• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Low Back Pain - Pipeline Review, H2 2012 Product Image

Low Back Pain - Pipeline Review, H2 2012

  • ID: 2335416
  • November 2012
  • 73 pages
  • Global Markets Direct

Low Back Pain – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Low Back Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Low Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Low Back Pain. Low Back Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Low Back Pain.
- A review of the Low Back Pain products under development by companies and universities/research institutes based on information READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Low Back Pain Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Low Back Pain 9
Low Back Pain Therapeutics under Development by Companies 11
Low Back Pain Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Low Back Pain Therapeutics – Products under Development by Companies 18
Low Back Pain Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Low Back Pain Therapeutics Development 20
DURECT Corporation 20
BioDelivery Sciences International, Inc. 21
Zogenix, Inc. 22
Astellas Pharma Inc. 23
Eisai Co., Ltd. 24
Pfizer Inc. 25
Purdue Pharma L.P. 26
Collegium Pharmaceutical, Inc. 27
Newron Pharmaceuticals S.p.A. 28
QRxPharma Limited 29
Sosei Co. Ltd. 30
Troikaa Pharmaceuticals Ltd. 31
Low Back Pain – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
bupivacaine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALO-02 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
buprenorphine hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
morphine sulfate + oxycodone hydrochloride CR - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ralfinamide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
cycloserine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
hydrocodone bitartrate ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SD-726 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
oxycodone ER - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
milnacipran - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
E2000 + Diclofenac Sodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
hydrocodone bitartrate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Diclofenac + Thiocolchicoside - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
anakinra - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AYX-2 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ASP-6973 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Low Back Pain Therapeutics – Drug Profile Updates 60
Low Back Pain Therapeutics – Discontinued Products 68
Low Back Pain Therapeutics - Dormant Products 69
Low Back Pain – Product Development Milestones 70
Featured News & Press Releases 70
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 70
Aug 29, 2012: Collegium Pharma Initiates Enrollment In Phase III Efficacy Study Of Oxycodone DETERx In Subjects With Moderate To Severe Chronic Lower Back Pain 70
Apr 17, 2012: Mesoblast Announces Intervertebral Disc Repair Phase II Trial Update 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Low Back Pain, H2 2012 9
Products under Development for Low Back Pain – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
DURECT Corporation, H2 2012 20
BioDelivery Sciences International, Inc., H2 2012 21
Zogenix, Inc., H2 2012 22
Astellas Pharma Inc., H2 2012 23
Eisai Co., Ltd., H2 2012 24
Pfizer Inc., H2 2012 25
Purdue Pharma L.P., H2 2012 26
Collegium Pharmaceutical, Inc., H2 2012 27
Newron Pharmaceuticals S.p.A., H2 2012 28
QRxPharma Limited, H2 2012 29
Sosei Co. Ltd., H2 2012 30
Troikaa Pharmaceuticals Ltd., H2 2012 31
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 37
Low Back Pain Therapeutics – Drug Profile Updates 60
Low Back Pain Therapeutics – Discontinued Products 68
Low Back Pain Therapeutics – Dormant Products 69

List of Figures
Number of Products under Development for Low Back Pain, H2 2012 9
Products under Development for Low Back Pain – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos